Technology Melior Pharmaceuticals | Melior Affiliate Melior Discovery Melior Pharmaceuticals leverages the proprietary technology if its affiliate company, Melior Discovery, to identify new indications for drugs that have existing clinical data in other indications Melior Discovery is a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning
About Melior Pharmaceuticals | Clinical Stage Diabetes, NASH, Parkinson . . . About Us Melior Pharmaceuticals is a mid-stage biopharmaceutical company developing a pipeline of de-risked therapies in areas with significant unmet needs Our lead clinical stage candidates are in the areas of diabetes, NASH, Parkinson’s Disease and sleep disorders We leverage the proprietary drug-repositioning technology of our affiliate company, Melior Discovery, to identify new targets
Tolimidone – Lyn Kinase Activator| Type 2 Diabetes, NASH Therapy Research Overview: Tolimidone is a novel, clinical stage drug candidate for the treatment of Type 2 Diabetes and Nonalcoholic Steatohepatis (NASH) Tolimidone improves glycemic control by selectively activating the enzyme lyn kinase, which has been shown to modulate the insulin-signaling pathway Tolimidone is the first described specific and direct activator of Lyn kinase that elicits glycemic control
Melior Announces Research Collaboration with Merck About Melior Melior Discovery and its sister companies, Melior Pharmaceuticals I, Inc and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE® platform comprised of multiplexed in vivo disease models
Tolimidone - Melior Pharmaceuticals Tolimidone A novel clinical stage drug candidate for treatment of Nonalcoholic Steatohepat Melior Pharmaceuticals is pioneering work in the area of lyn kinase activation Tolimidone is the most advance lyn kinase activator from Melior’s pipeline, currently in development for Type 2 Diabetes Mellitus (T2DM) and nonalcoholic steatohepatitis (NASH)